Scalper1 News
Beleaguered biotech stock Arrowhead Research (ARWR) gapped up sharply Thursday morning after the company reported positive midstage trial data on its hepatitis B drug candidate. Arrowhead kicked off its analyst day by releasing top-line data from its phase-two trial of its drug ARC-520 in patients who tested positive for the hepatitis B virus E-antigen (HBeAg), a kind of antigen that the virus produces to resist the body’s immune system. Patients Scalper1 News
Scalper1 News